{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:13:08Z","timestamp":1762377188279,"version":"build-2065373602"},"reference-count":207,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Psychosis in Parkinson\u2019s disease (PDP) represents a common and debilitating condition that complicates Parkinson\u2019s disease (PD), mainly in the later stages. The spectrum of psychotic symptoms are heterogeneous, ranging from minor phenomena of mild illusions, passage hallucinations and sense of presence to severe psychosis consisting of visual hallucinations (and rarely, auditory and tactile or gustatory) and paranoid delusions. PDP is associated with increased caregiver stress, poorer quality of life for patients and carers, reduced survival and risk of institutionalization with a significant burden on the healthcare system. Although several risk factors for PDP development have been identified, such as aging, sleep disturbances, long history of PD, cognitive impairment, depression and visual disorders, the pathophysiology of psychosis in PD is complex and still insufficiently clarified. Additionally, several drugs used to treat PD can aggravate or even precipitate PDP. Herein, we reviewed and critically analyzed recent studies exploring the genetic architecture of psychosis in PD in order to further understand the pathophysiology of PDP, the risk factors as well as the most suitable therapeutic strategies.<\/jats:p>","DOI":"10.3390\/genes13061099","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T01:43:27Z","timestamp":1655775807000},"page":"1099","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Psychosis in Parkinson\u2019s Disease: A Lesson from Genetics"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-3384","authenticated-orcid":false,"given":"Efthalia","family":"Angelopoulou","sequence":"first","affiliation":[{"name":"Department of Neurology, Eginition University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-8711","authenticated-orcid":false,"given":"Anastasia","family":"Bougea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Eginition University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8863-3635","authenticated-orcid":false,"given":"Sokratis G.","family":"Papageorgiou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Eginition University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-5974","authenticated-orcid":false,"given":"Chiara","family":"Villa","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.14802\/jmd.15003","article-title":"Many Faces of Parkinson\u2019s Disease: Non-Motor Symptoms of Parkinson\u2019s Disease","volume":"8","author":"Lee","year":"2015","journal-title":"J. Mov. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101618","DOI":"10.1016\/j.arr.2022.101618","article-title":"Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson\u2019s disease.Prevention of neuroinflammation in Parkinson\u2019s disease","volume":"78","author":"Kip","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_3","first-page":"504","article-title":"Parkinson\u2019s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a009258","DOI":"10.1101\/cshperspect.a009258","article-title":"Parkinson\u2019s disease and parkinsonism: Neuropathology","volume":"2","author":"Dickson","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"ref_6","first-page":"e13275","article-title":"Spectrum of Non-Motor Symptoms in Parkinson\u2019s Disease","volume":"13","author":"Kumaresan","year":"2021","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00702-015-1400-x","article-title":"Psychosis in Parkinson\u2019s disease: Identification, prevention and treatment","volume":"123","author":"Levin","year":"2016","journal-title":"J. Neural. Transm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.4088\/PCC.18l02355","article-title":"Pimavanserin for Parkinson Disease Psychosis","volume":"21","author":"Mohanty","year":"2019","journal-title":"Prim. Care Companion CNS Disord."},{"key":"ref_9","first-page":"100119","article-title":"High frequency of psychosis in late-stage Parkinso\u0144s disease","volume":"5","author":"Chendo","year":"2021","journal-title":"Clin. Park Relat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Eichel, H.V., Heine, J., Wegner, F., Rogozinski, S., Stiel, S., Groh, A., Krey, L., H\u00f6glinger, G.U., and Klietz, M. (2022). Neuropsychiatric Symptoms in Parkinson\u2019s Disease Patients Are Associated with Reduced Health-Related Quality of Life and Increased Caregiver Burden. Brain Sci., 12.","DOI":"10.3390\/brainsci12010089"},{"key":"ref_11","first-page":"3256542","article-title":"Management of Psychosis in Parkinson\u2019s Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition","volume":"2017","author":"Taddei","year":"2017","journal-title":"Parkinsons Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: Report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson\u2019s Disease: Epidemiology, Pathophysiology, and Management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.2147\/DDDT.S114147","article-title":"Anticonvulsant effects of isomeric nonimidazole histamine H(3) receptor antagonists","volume":"10","author":"Sadek","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(18)30127-3","article-title":"Risk factors for non-motor symptoms in Parkinson\u2019s disease","volume":"17","author":"Marinus","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/mds.23806","article-title":"Disease-related and genetic correlates of psychotic symptoms in Parkinson\u2019s disease","volume":"26","author":"Factor","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2016.03.005","article-title":"Genetic substrates of psychosis in patients with Parkinson\u2019s disease: A critical review","volume":"364","author":"Lenka","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104782","DOI":"10.1016\/j.nbd.2020.104782","article-title":"Genetics of Parkinson\u2019s disease: An introspection of its journey towards precision medicine","volume":"137","author":"Kim","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","article-title":"Parkinson\u2019s disease: From monogenic forms to genetic susceptibility factors","volume":"18","author":"Lesage","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.irn.2017.01.009","article-title":"Genetics of Parkinson\u2019s Disease: Genotype-Phenotype Correlations","volume":"132","author":"Koros","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","article-title":"Autosomal dominant Parkinson\u2019s disease caused by SNCA duplications","volume":"22","author":"Konno","year":"2016","journal-title":"Parkinsonism. Relat. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"\u03b1-Synuclein locus triplication causes Parkinson\u2019s disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"648588","DOI":"10.3389\/fneur.2021.648588","article-title":"Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings","volume":"12","author":"Guadagnolo","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-49969-7_2","article-title":"Clinical Features of LRRK2 Carriers with Parkinson\u2019s Disease","volume":"14","author":"Kestenbaum","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ane.12616","article-title":"An updated review of Parkinson\u2019s disease genetics and clinicopathological correlations","volume":"135","author":"Ferreira","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1326-9-47","article-title":"The role of the LRRK2 gene in Parkinsonism","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11064-013-1073-5","article-title":"The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson\u2019s disease","volume":"39","author":"Rideout","year":"2014","journal-title":"Neurochem. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13024-016-0140-1","article-title":"LRRK2 at the interface of autophagosomes, endosomes and lysosomes","volume":"11","author":"Roosen","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.28365","article-title":"Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons","volume":"36","author":"Hanss","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.12.001","article-title":"Role of the VPS35 D620N mutation in Parkinson\u2019s disease","volume":"36","author":"Mohan","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson\u2019s disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"706145","DOI":"10.3389\/fneur.2021.706145","article-title":"Frequency of Heterozygous Parkin (PRKN) Variants and Penetrance of Parkinson\u2019s Disease Risk Markers in the Population-Based CHRIS Cohort","volume":"12","author":"Raftopoulou","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/humu.20436","article-title":"Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism","volume":"28","author":"Lesage","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/humu.22808","article-title":"Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin","volume":"36","author":"Fiesel","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3389\/fcell.2020.00423","article-title":"Exploring the Impact of PARK2 Mutations on the Total and Mitochondrial Proteome of Human Skin Fibroblasts","volume":"8","author":"Zilocchi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.conb.2021.09.005","article-title":"PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson\u2019s disease","volume":"72","author":"Agarwal","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JPD-160989","article-title":"PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson\u2019s Disease Pathobiology?","volume":"7","author":"Truban","year":"2017","journal-title":"J. Parkinsons. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s43042-021-00208-2","article-title":"Deconstructing the molecular genetics behind the PINK1\/Parkin axis in Parkinson\u2019s disease using Drosophila melanogaster as a model organism","volume":"22","author":"Ganesan","year":"2021","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mencke, P., Boussaad, I., Romano, C.D., Kitami, T., Linster, C.L., and Kr\u00fcger, R. (2021). The Role of DJ-1 in Cellular Metabolism and Pathophysiological Implications for Parkinson\u2019s Disease. Cells, 10.","DOI":"10.3390\/cells10020347"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Krebiehl, G., Ruckerbauer, S., Burbulla, L.F., Kieper, N., Maurer, B., Waak, J., Wolburg, H., Gizatullina, Z., Gellerich, F.N., and Woitalla, D. (2010). Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson\u2019s disease-associated protein DJ-1. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009367"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson\u2019s disease: Current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1389202914666131210212745","article-title":"Association studies of sporadic Parkinson\u2019s disease in the genomic era","volume":"15","author":"Ross","year":"2014","journal-title":"Curr. Genom."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/ng.3955","article-title":"A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci","volume":"49","author":"Chang","year":"2017","journal-title":"Nat. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson\u2019s disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00441-018-2817-y","article-title":"Genetic risk factors in Parkinson\u2019s disease","volume":"373","author":"Billingsley","year":"2018","journal-title":"Cell Tissue Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1093\/hmg\/ddp265","article-title":"Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human \u03b1-synuclein in transgenic mouse brain","volume":"18","author":"Cronin","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.296.6.661","article-title":"Collaborative analysis of \u03b1-synuclein gene promoter variability and Parkinson disease","volume":"296","author":"Maraganore","year":"2006","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lill, C.M., Roehr, J.T., McQueen, M.B., Kavvoura, F.K., Bagade, S., Schjeide, B.M., Schjeide, L.M., Meissner, E., Zauft, U., and Allen, N.C. (2012). Comprehensive research synopsis and systematic meta-analyses in Parkinson\u2019s disease genetics: The PDGene database. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002548"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson\u2019s disease: A case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.parkreldis.2006.12.001","article-title":"Lrrk2 G2385R is an ancestral risk factor for Parkinson\u2019s disease in Asia","volume":"13","author":"Farrer","year":"2007","journal-title":"Parkinsonism. Relat. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ana.21405","article-title":"Analysis of Lrrk2 R1628P as a risk factor for Parkinson\u2019s disease","volume":"64","author":"Ross","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JAD-2011-102124","article-title":"A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia","volume":"26","author":"Villa","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","article-title":"MAPT mutations, tauopathy, and mechanisms of neurodegeneration","volume":"99","author":"Strang","year":"2019","journal-title":"Lab. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ruiz-Gabarre, D., Carnero-Espejo, A., \u00c1vila, J., and Garc\u00eda-Escudero, V. (2022). What\u2019s in a Gene? The Outstanding Diversity of MAPT. Cells, 11.","DOI":"10.3390\/cells11050840"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.parkreldis.2008.03.001","article-title":"From 1997 to 2007: A decade journey through the H1 haplotype on 17q21 chromosome","volume":"15","author":"Kalinderi","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/hdy.2008.70","article-title":"H1 tau haplotype-related genomic variation at 17q21.3 as an Asian heritage of the European Gypsy population","volume":"101","author":"Almos","year":"2008","journal-title":"Heredity"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/ng.487","article-title":"Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease","volume":"41","author":"Schulte","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1469-1809.2009.00560.x","article-title":"Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease","volume":"74","author":"Edwards","year":"2010","journal-title":"Ann. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000082956","article-title":"The tau gene haplotype h1 confers a susceptibility to Parkinson\u2019s disease","volume":"53","author":"Zhang","year":"2005","journal-title":"Eur. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcmd.2006.02.004","article-title":"Increased incidence of Parkinson disease among relatives of patients with Gaucher disease","volume":"36","author":"Halperin","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher\u2019s disease with Parkinson\u2019s disease: Clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/mds.28416","article-title":"The Rostock International Parkinson\u2019s Disease (ROPAD) Study: Protocol and Initial Findings","volume":"36","author":"Skrahina","year":"2021","journal-title":"Mov. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10545-014-9714-7","article-title":"The significance of GBA for Parkinson\u2019s disease","volume":"37","author":"Brockmann","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00702-021-02421-0","article-title":"Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson\u2019s disease: Mutational spectrum and clinical features","volume":"129","author":"Lim","year":"2022","journal-title":"J. Neural. Transm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2021.08.230","article-title":"Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways","volume":"175","author":"Vieira","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajhg.2010.01.011","article-title":"Mutations in the small GTPase gene RAB39B are responsible for X-linked mental retardation associated with autism, epilepsy, and macrocephaly","volume":"86","author":"Giannandrea","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/humu.22497","article-title":"Increased dosage of RAB39B affects neuronal development and could explain the cognitive impairment in male patients with distal Xq28 copy number gains","volume":"35","author":"Vanmarsenille","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ajhg.2014.10.015","article-title":"Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with \u03b1-synuclein pathology","volume":"95","author":"Wilson","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1212\/NXG.0000000000000009","article-title":"Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease","volume":"1","author":"Lesage","year":"2015","journal-title":"Neurol. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/jcp.29962","article-title":"RAB39B\u2019s role in membrane traffic, autophagy, and associated neuropathology","volume":"236","author":"Tang","year":"2021","journal-title":"J. Cell Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mds.27270","article-title":"The emerging role of Rab GTPases in the pathogenesis of Parkinson\u2019s disease","volume":"33","author":"Gao","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fneur.2020.00523","article-title":"Genetic Analysis of RAB39B in an Early-Onset Parkinson\u2019s Disease Cohort","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"34502","DOI":"10.1038\/srep34502","article-title":"RAB39B gene mutations are not linked to familial Parkinson\u2019s disease in China","volume":"6","author":"Kang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.neurol.2018.08.004","article-title":"The genetic landscape of Parkinson\u2019s disease","volume":"174","author":"Lunati","year":"2018","journal-title":"Rev. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ng.3589","article-title":"Identification of TMEM230 mutations in familial Parkinson\u2019s disease","volume":"48","author":"Deng","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(18)30179-0","article-title":"LRP10 genetic variants in familial Parkinson\u2019s disease and dementia with Lewy bodies: A genome-wide linkage and sequencing study","volume":"17","author":"Quadri","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.1073\/pnas.1809969115","article-title":"Coding mutations in NUS1 contribute to Parkinson\u2019s disease","volume":"115","author":"Guo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1038\/emboj.2011.147","article-title":"Nogo-B receptor is necessary for cellular dolichol biosynthesis and protein N-glycosylation","volume":"30","author":"Harrison","year":"2011","journal-title":"EMBO J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cmet.2009.07.003","article-title":"Nogo-B receptor stabilizes Niemann-Pick type C2 protein and regulates intracellular cholesterol trafficking","volume":"10","author":"Harrison","year":"2009","journal-title":"Cell Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"300.e301","DOI":"10.1016\/j.neurobiolaging.2020.11.007","article-title":"Replication assessment of NUS1 variants in Parkinson\u2019s disease","volume":"101","author":"Bustos","year":"2021","journal-title":"Neurobiol. Aging"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1093\/brain\/awz205","article-title":"Arylsulfatase A, a genetic modifier of Parkinson\u2019s disease, is an \u03b1-synuclein chaperone","volume":"142","author":"Lee","year":"2019","journal-title":"Brain"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Angelopoulou, E., Paudel, Y.N., Villa, C., and Piperi, C. (2020). Arylsulfatase A (ASA) in Parkinson\u2019s Disease: From Pathogenesis to Biomarker Potential. Brain Sci., 10.","DOI":"10.3390\/brainsci10100713"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1093\/brain\/awz340","article-title":"ARSA variants in \u03b1-synucleinopathies","volume":"142","author":"Makarious","year":"2019","journal-title":"Brain"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1021\/acschemneuro.1c00295","article-title":"APOE Genotype and Alzheimer\u2019s Disease: The Influence of Lifestyle and Environmental Factors","volume":"12","author":"Angelopoulou","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1212\/01.WNL.0000138612.24301.32","article-title":"ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD","volume":"63","author":"Chang","year":"2004","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.schres.2018.12.010","article-title":"Apolipoprotein E-epsilon4 allele predicts escalation of psychotic symptoms in late adulthood","volume":"206","author":"Jonas","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2022.03.005","article-title":"Smoking is associated with age at disease onset in Parkinson\u2019s disease","volume":"97","author":"Rosas","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/mds.20663","article-title":"Presence of an APOE4 allele results in significantly earlier onset of Parkinson\u2019s disease and a higher risk with dementia","volume":"21","author":"Pankratz","year":"2006","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"631145","DOI":"10.3389\/fneur.2021.631145","article-title":"APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson\u2019s Disease","volume":"12","author":"Tunold","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e12884","DOI":"10.1097\/MD.0000000000012884","article-title":"The genetic association between apolipoprotein E gene polymorphism and Parkinson disease: A meta-Analysis of 47 studies","volume":"97","author":"Li","year":"2018","journal-title":"Medicine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","article-title":"APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology","volume":"91","author":"Dickson","year":"2018","journal-title":"Neurology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/WAD.0000000000000479","article-title":"Role of Apolipoprotein E in the Clinical Profile of Atypical Parkinsonian Syndromes","volume":"36","author":"Nasri","year":"2022","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11920-016-0730-1","article-title":"Current Understanding of Psychosis in Parkinson\u2019s Disease","volume":"18","author":"Ojo","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_98","first-page":"226","article-title":"The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson\u2019s disease","volume":"22","author":"Nunez","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archneur.58.2.209","article-title":"Genetic variation analysis in parkinson disease patients with and without hallucinations: Case-control study","volume":"58","author":"Goetz","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.20481","article-title":"Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson\u2019s disease: Relationship to dementia and hallucinations","volume":"20","author":"Camicioli","year":"2005","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2006.12.008","article-title":"Phenotypic associations of tau and ApoE in Parkinson\u2019s disease","volume":"414","author":"Papapetropoulos","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.2005.00535.x","article-title":"Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson\u2019s disease","volume":"113","author":"Feldman","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.parkreldis.2014.02.001","article-title":"Clinical and pathologic presentation in Parkinson\u2019s disease by apolipoprotein e4 allele status","volume":"20","author":"Monsell","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tips.2013.07.005","article-title":"Mechanisms of dopamine transporter regulation in normal and disease states","volume":"34","author":"Vaughan","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2004.02.065","article-title":"The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women","volume":"362","author":"Limosin","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3346\/jkms.2000.15.4.449","article-title":"Association of the dopamine transporter gene with Parkinson\u2019s disease in Korean patients","volume":"15","author":"Kim","year":"2000","journal-title":"J. Korean Med. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/mds.870120523","article-title":"Association of a polymorphism in the dopamine-transporter gene with Parkinson\u2019s disease","volume":"12","author":"Leighton","year":"1997","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_108","first-page":"346","article-title":"Association between genetic polymorphism of dopamine transporter gene and susceptibility to Parkinson\u2019s disease","volume":"80","author":"Wang","year":"2000","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.WNL.0000068009.32067.A1","article-title":"L-dopa-induced adverse effects in PD and dopamine transporter gene polymorphism","volume":"60","author":"Kaiser","year":"2003","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.mp.4000921","article-title":"Polymorphisms in the 3\u2032-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression","volume":"7","author":"Miller","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3233\/JPD-212716","article-title":"Clinical and Genetic Analysis of Psychosis in Parkinson\u2019s Disease","volume":"11","author":"Radojevic","year":"2021","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S1461145712001666","article-title":"Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson\u2019s disease","volume":"16","author":"Francisconi","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neulet.2003.11.006","article-title":"Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson\u2019s disease","volume":"355","author":"Wang","year":"2004","journal-title":"Neurosci. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jcph.1394","article-title":"Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson\u2019s Disease","volume":"59","author":"Duarte","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fphar.2019.00008","article-title":"Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson\u2019s Disease","volume":"10","author":"Redensek","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_116","first-page":"403039","article-title":"Dopamine receptors and Parkinson\u2019s disease","volume":"2011","author":"Hisahara","year":"2011","journal-title":"Int. J. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","article-title":"Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson\u2019s disease","volume":"10","author":"Makoff","year":"2000","journal-title":"Pharmacogenetics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF02346178","article-title":"Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia","volume":"97","author":"Shaikh","year":"1996","journal-title":"Hum. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/sj.mp.4000288","article-title":"The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response","volume":"3","author":"Malhotra","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","article-title":"Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease","volume":"55","author":"Sweet","year":"1998","journal-title":"Arch. Neurol."},{"key":"ref_121","first-page":"1642087","article-title":"The Association between DRD3 Ser9Gly Polymorphism and Depression Severity in Parkinson\u2019s Disease","volume":"2019","author":"Zhi","year":"2019","journal-title":"Parkinson\u2019s Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-016-2111-4","article-title":"Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson\u2019s patients","volume":"72","author":"Ferrari","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.amjhyper.2004.07.013","article-title":"Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension","volume":"17","author":"Beige","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/archpsyc.61.6.597","article-title":"Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations","volume":"61","author":"Xu","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0196-9781(94)90104-X","article-title":"Biological actions of cholecystokinin","volume":"15","author":"Crawley","year":"1994","journal-title":"Peptides"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0196-9781(01)00442-9","article-title":"An introduction to neuronal cholecystokinin","volume":"22","author":"Beinfeld","year":"2001","journal-title":"Peptides"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0006-8993(82)91135-0","article-title":"CCK-8-Immunoreactivity distribution in human brain: Selective decrease in the substantia nigra from parkinsonian patients","volume":"243","author":"Studler","year":"1982","journal-title":"Brain Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0165-6147(91)90558-A","article-title":"Cholecystokinin-dopamine interactions","volume":"12","author":"Crawley","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1034\/j.1399-0004.1999.560508.x","article-title":"Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson\u2019s disease","volume":"56","author":"Fujii","year":"1999","journal-title":"Clin. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008571-200306000-00008","article-title":"Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson\u2019s disease","volume":"13","author":"Wang","year":"2003","journal-title":"Pharmacogenetics"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jad.2011.09.011","article-title":"Cholecystokinin system genes: Associations with panic and other psychiatric disorders","volume":"136","author":"Wilson","year":"2012","journal-title":"J. Affect. Disord."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.mp.4000705","article-title":"Function of the C-36 to T polymorphism in the human cholecystokinin gene promoter","volume":"5","author":"Hansen","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archneur.61.8.1280","article-title":"Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: An analysis of the cholecystokinin system","volume":"61","author":"Goldman","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/mds.23655","article-title":"Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson\u2019s disease hallucinations","volume":"26","author":"Goldman","year":"2011","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1523\/JNEUROSCI.21-22-09043.2001","article-title":"Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: A potential role for Homer","volume":"21","author":"Swanson","year":"2001","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.neuint.2012.06.014","article-title":"Scaffold protein Homer 1: Implications for neurological diseases","volume":"61","author":"Luo","year":"2012","journal-title":"Neurochem. Int."},{"key":"ref_137","first-page":"289","article-title":"Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson\u2019s disease patients","volume":"14","author":"Altmann","year":"2014","journal-title":"Pharm. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.conb.2006.05.002","article-title":"Homer proteins: Implications for neuropsychiatric disorders","volume":"16","author":"Szumlinski","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.cellsig.2013.09.004","article-title":"Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson\u2019s disease","volume":"25","author":"Chen","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1460-9568.2006.05264.x","article-title":"Deep brain stimulation in a rat model modulates TH, CaMKIIa and Homer1 gene expression","volume":"25","author":"Henning","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainres.2006.11.011","article-title":"The dopamine D1 receptor agonist, but not the D2 receptor agonist, induces gene expression of Homer 1a in rat striatum and nucleus accumbens","volume":"1131","author":"Yamada","year":"2007","journal-title":"Brain Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000230689","article-title":"HOMER1 promoter analysis in Parkinson\u2019s disease: Association study with psychotic symptoms","volume":"59","author":"Annesi","year":"2009","journal-title":"Neuropsychobiology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.hrtlng.2022.04.012","article-title":"Experiences of ethnic discrimination and COMT rs4680 polymorphism are associated with depressive symptoms in Latinx adults at risk for cardiovascular disease","volume":"55","author":"Key","year":"2022","journal-title":"Heart Lung J. Crit. Care"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"24","DOI":"10.17712\/nsj.2022.1.20210045","article-title":"COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population","volume":"27","author":"Aytac","year":"2022","journal-title":"Neurosciences"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2012.09.062","article-title":"No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias","volume":"531","author":"Creese","year":"2012","journal-title":"Neurosci. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","article-title":"Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson\u2019s disease","volume":"20","author":"Devos","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YPG.0b013e3283351194","article-title":"Angiotensin-converting enzyme polymorphism in schizophrenia, bipolar disorders, and their first-degree relatives","volume":"20","author":"Kucukali","year":"2010","journal-title":"Psychiatr. Genet."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4899-1376-0_10","article-title":"Interactions of angiotensin II with central dopamine","volume":"396","author":"Jenkins","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"837890","DOI":"10.3389\/fphar.2022.837890","article-title":"Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson\u2019s Disease: A Nationwide Cohort Study","volume":"13","author":"Jo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(02)00081-3","article-title":"Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson\u2019s disease","volume":"199","author":"Lin","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Fedosova, A., Titova, N., Kokaeva, Z., Shipilova, N., Katunina, E., and Klimov, E. (2021). Genetic Markers as Risk Factors for the Development of Impulsive-Compulsive Behaviors in Patients with Parkinson\u2019s Disease Receiving Dopaminergic Therapy. J. Pers. Med., 11.","DOI":"10.3390\/jpm11121321"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jns.2006.10.018","article-title":"Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson\u2019s disease","volume":"252","author":"Lin","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2008.08.017","article-title":"Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson\u2019s disease and of L-dopa-induced adverse effects","volume":"276","author":"Pascale","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"9879","DOI":"10.1038\/s41598-021-89300-6","article-title":"Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson\u2019s disease","volume":"11","author":"Ezquerra","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2174\/1389202914666131210212521","article-title":"Pharmacogenetics of Parkinson\u2019s disease\u2014Through mechanisms of drug actions","volume":"14","author":"Drozdzik","year":"2013","journal-title":"Curr. Genom."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410220207","article-title":"Aminergic systems in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"22","author":"Zweig","year":"1987","journal-title":"Ann. Neurol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2005.11.005","article-title":"Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson\u2019s disease","volume":"12","author":"Burn","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/089198879901200202","article-title":"Depression and anxiety in Parkinson\u2019s disease: Possible effect of genetic variation in the serotonin transporter","volume":"12","author":"Menza","year":"1999","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.mp.4000849","article-title":"Allelic variation of serotonin transporter expression is associated with depression in Parkinson\u2019s disease","volume":"6","author":"Mossner","year":"2001","journal-title":"Mol. Psychiatry"},{"key":"ref_161","first-page":"293","article-title":"5-HT2A receptor gene polymorphism and negative symptoms in first episode (drug-naive) Chinese Han nationality individuals with schizophrenia","volume":"33","author":"Wang","year":"2008","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban = J. Cent. South Univ. Med. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/109065703322783662","article-title":"Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): Association studies with psychosis in Alzheimer disease","volume":"7","author":"Rocchi","year":"2003","journal-title":"Genet. Test."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","article-title":"The neuropsychiatry of Parkinson\u2019s disease: Advances and challenges","volume":"21","author":"Weintraub","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neulet.2007.06.028","article-title":"Visual hallucinations in Parkinson\u2019s disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes","volume":"422","author":"Kiferle","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jagp.2012.11.001","article-title":"Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias","volume":"22","author":"Creese","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/ajmg.b.30758","article-title":"Genetic association between \u03b1-synuclein and idiopathic Parkinson\u2019s disease","volume":"147B","author":"Kay","year":"2008","journal-title":"Am. J. Med. Genetics. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11910-012-0283-6","article-title":"Neuroinflammation and non-motor symptoms: The dark passenger of Parkinson\u2019s disease?","volume":"12","author":"Barnum","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_168","first-page":"898192","article-title":"Interleukin-6 May Contribute to Mortality in Parkinson\u2019s Disease Patients: A 4-Year Prospective Study","volume":"2015","author":"Dufek","year":"2015","journal-title":"Parkinson\u2019s Dis."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Sawada, H., Oeda, T., Umemura, A., Tomita, S., Hayashi, R., Kohsaka, M., Yamamoto, K., Sudoh, S., and Sugiyama, H. (2014). Subclinical elevation of plasma C-reactive protein and illusions\/hallucinations in subjects with Parkinson\u2019s disease: Case-control study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085886"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ijnp\/pyaa028","article-title":"Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson\u2019s Disease","volume":"23","author":"Redensek","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2015.07.018","article-title":"Clinical studies of neuroinflammatory mechanisms in schizophrenia","volume":"176","author":"Watkins","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1267855","DOI":"10.1080\/20010001.2017.1267855","article-title":"Neurochemical and motor changes in mice with combined mutations linked to Parkinson\u2019s disease","volume":"7","author":"Bai","year":"2017","journal-title":"Pathobiol. Aging Age Relat. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.2147\/NDT.S272278","article-title":"Association Between Glutathione Peroxidase-1 (GPx-1) Polymorphisms and Schizophrenia in the Chinese Han Population","volume":"16","author":"Shao","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1744-9081-7-42","article-title":"Association study of monoamine oxidase A\/B genes and schizophrenia in Han Chinese","volume":"7","author":"Wei","year":"2011","journal-title":"Behav. Brain Funct. BBF"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2174\/1871530320999201113103730","article-title":"UCP2 and CFH Gene Variants with Genetic Susceptibility to Schizophrenia in Turkish Population","volume":"21","author":"Nursal","year":"2021","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/mds.27466","article-title":"Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson\u2019s disease","volume":"33","author":"Lohle","year":"2018","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/pgs.15.147","article-title":"Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients","volume":"17","author":"Jenko","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1038\/s41380-019-0617-8","article-title":"Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome","volume":"26","author":"Greening","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2006.02.054","article-title":"Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms","volume":"401","author":"Numata","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"e8443","DOI":"10.1590\/1414-431x20198443","article-title":"Association between BDNF G196A (Val66Met) polymorphism and cognitive impairment in patients with Parkinson\u2019s disease: A meta-analysis","volume":"52","author":"Wang","year":"2019","journal-title":"Braz. J. Med. Biol. Res. = Rev. Bras. Pesqui. Med. Biol."},{"key":"ref_181","first-page":"9","article-title":"Brain-Derived Neurotrophic Factor: Three Ligands, Many Actions","volume":"126","author":"Hempstead","year":"2015","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0404.2009.01253.x","article-title":"Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson\u2019s disease","volume":"122","author":"Gao","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"587992","DOI":"10.3389\/fneur.2020.587992","article-title":"Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson\u2019s Disease","volume":"11","author":"Ramezani","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mdc3.12444","article-title":"Pharmacogenetics of Parkinson\u2019s Disease in Clinical Practice","volume":"4","author":"Corvol","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/jnnp-2018-318107","article-title":"Early use of donepezil against psychosis and cognitive decline in Parkinson\u2019s disease: A randomised controlled trial for 2 years","volume":"89","author":"Sawada","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hup.930","article-title":"Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder","volume":"23","author":"Adams","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"814430","DOI":"10.3389\/fnins.2022.814430","article-title":"Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson\u2019s Disease Mouse Model","volume":"16","author":"Zhang","year":"2022","journal-title":"Front. Neurosci."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Chen, T., Zhu, J., Zhang, C., Huo, K., Fei, Z., and Jiang, X.F. (2013). Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: Potential role of Homer1. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055601"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/17512433.2017.1369405","article-title":"Pimavanserin, a novel antipsychotic for management of Parkinson\u2019s disease psychosis","volume":"10","author":"Kianirad","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Magistrelli, L., Ferrari, M., Furgiuele, A., Milner, A.V., Contaldi, E., Comi, C., Cosentino, M., and Marino, F. (2021). Polymorphisms of Dopamine Receptor Genes and Parkinson\u2019s Disease: Clinical Relevance and Future Perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073781"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \u201cbenign hallucinations\u201d in Parkinson disease","volume":"63","author":"Goetz","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/brain\/awaa270","article-title":"Differences in network controllability and regional gene expression underlie hallucinations in Parkinson\u2019s disease","volume":"143","author":"Zarkali","year":"2020","journal-title":"Brain J. Neurol."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Zhu, M., Cortese, G.P., and Waites, C.L. (2018). Parkinson\u2019s disease-linked Parkin mutations impair glutamatergic signaling in hippocampal neurons. BMC Biol., 16.","DOI":"10.1186\/s12915-018-0567-7"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/mds.27352","article-title":"Genotype-Phenotype Relations for the Parkinson\u2019s Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review","volume":"33","author":"Kasten","year":"2018","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Yamane, T., Suzui, S., Kitaura, H., Takahashi-Niki, K., Iguchi-Ariga, S.M., and Ariga, H. (2013). Transcriptional activation of the cholecystokinin gene by DJ-1 through interaction of DJ-1 with RREB1 and the effect of DJ-1 on the cholecystokinin level in mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078374"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Repici, M., and Giorgini, F. (2019). DJ-1 in Parkinson\u2019s Disease: Clinical Insights and Therapeutic Perspectives. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091377"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1712.e9","DOI":"10.1016\/j.neurobiolaging.2012.12.020","article-title":"Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson\u2019s disease","volume":"34","author":"Brighina","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.30773\/pi.2020.0023","article-title":"The Gene Polymorphism of VMAT2 Is Associated with Risk of Schizophrenia in Male Han Chinese","volume":"17","author":"Han","year":"2020","journal-title":"Psychiatry Investig."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.psc.2009.12.003","article-title":"The role of genetics in the etiology of schizophrenia","volume":"33","author":"Gejman","year":"2010","journal-title":"Psychiatr. Clin. N. Am."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"e993","DOI":"10.1038\/tp.2016.242","article-title":"Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder","volume":"7","author":"Charney","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","article-title":"Electronic address, d.r.v.e.; Bipolar, D.; Schizophrenia Working Group of the Psychiatric Genomics, C. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes","volume":"173","author":"Bipolar","year":"2018","journal-title":"Cell"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parkreldis.2019.08.013","article-title":"The relationship between environmental factors and different Parkinson\u2019s disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson\u2019s disease","volume":"67","author":"Angelopoulou","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JPD-223188","article-title":"The Promise of Mendelian Randomization in Parkinson\u2019s Disease: Has the Smoke Cleared Yet for Smoking and Parkinson\u2019s Disease Risk?","volume":"12","author":"Ritz","year":"2022","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199602000-00006","article-title":"The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking","volume":"6","author":"Comings","year":"1996","journal-title":"Pharmacogenetics"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/mgme.2001.3208","article-title":"Cholecystokinin (CCK) gene as a possible risk factor for smoking: A replication in two independent samples","volume":"73","author":"Comings","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drugalcdep.2015.05.024","article-title":"Association between monoamine oxidase gene polymorphisms and smoking behavior: A meta-analysis","volume":"153","author":"Yang","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Happonen, P., Voutilainen, S., Tuomainen, T.P., and Salonen, J.T. (2006). Catechol-o-methyltransferase gene polymorphism modifies the effect of coffee intake on incidence of acute coronary events. PLoS ONE, 1.","DOI":"10.1371\/journal.pone.0000117"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/1099\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:35:37Z","timestamp":1760139337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/6\/1099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":207,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["genes13061099"],"URL":"https:\/\/doi.org\/10.3390\/genes13061099","relation":{},"ISSN":["2073-4425"],"issn-type":[{"type":"electronic","value":"2073-4425"}],"subject":[],"published":{"date-parts":[[2022,6,20]]}}}